

South Africa

Tuberculosis profile

Population 2015

54 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	25 (21–29)	46 (39–53)
Mortality (HIV+TB only)	73 (27–140)	133 (50–256)
Incidence (includes HIV+TB)	454 (294–649)	834 (539–1 190)
Incidence (HIV+TB only)	258 (165–370)	473 (303–680)
Incidence (MDR/RR-TB)**	20 (13–27)	37 (24–50)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0–14 years	> 14 years	Total
Females	16 (6.9–25)	175 (91–260)	191 (98–285)
Males	17 (9.8–23)	246 (173–320)	263 (182–343)
Total	33 (21–44)	422 (327–516)	454 (294–649)

TB case notifications, 2015	
Total cases notified	294 603
Total new and relapse	287 224
- % tested with rapid diagnostics at time of diagnosis	64%
- % with known HIV status	97%
- % pulmonary	90%
- % bacteriologically confirmed among pulmonary	60%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	63% (44–98)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.22 (0.1–0.42)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	157 505	57%
- on antiretroviral therapy	133 116	85%






Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			10 000 (8 200–12 000)
Estimated % of TB cases with MDR/RR-TB	3.5% (2.8–4.2)	7.1% (5.3–8.9)	
% notified tested for rifampicin resistance		65%	71%
MDR/RR-TB cases tested for resistance to second-line drugs			7 402
Laboratory-confirmed cases		MDR/RR-TB: 19 613, XDR-TB: 1 024	
Patients started on treatment ****		MDR/RR-TB: 12 527, XDR-TB: 730	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	78%	319 752
Previously treated cases, excluding relapse, registered in 2014	63%	4 652
HIV-positive TB cases, all types, registered in 2014	76%	183 697
MDR/RR-TB cases started on second-line treatment in 2013	48%	10 614
XDR-TB cases started on second-line treatment in 2013	24%	611

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	38%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	300
Funding source: 81% domestic, 12% international, 7% unfunded	

* Ranges represent uncertainty intervals
 ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
 *** Includes cases with unknown previous TB treatment history
 **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed



Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-07-26

Data: www.who.int/tb/data